CPT code 64650 represents a minimally invasive, office- or outpatient-based injection of a chemical agent into the eccrine glands of both axillae to treat focal hyperhidrosis. Nationally, this code matters because it identifies a common specialty procedure for patients with bothersome axillary sweating and drives coverage, billing, and utilization discussions across payers. Payors commonly involved in coverage and reimbursement for this service include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

Readers will learn what CPT code 64650 denotes clinically, how it is typically delivered (office or outpatient procedural setting), and which major payers are relevant for coverage considerations. The publication provides benchmarks and policy context around procedure coding, typical sites of service, and common billing practices where available. It also outlines clinical context for when bilateral axillary eccrine gland injection is used as a treatment for hyperhidrosis.

Data not available in the input is noted where payer-specific rates, associated taxonomies, ICD-10 mappings, and related codes would normally appear. The focus is national in scope and intended to inform billing staff, practice managers, and policy analysts about the code’s clinical purpose and administrative implications.